Description

Breyanzi is a medication used in the treatment of certain types of blood cancers, specifically large B-cell lymphoma. It is a type of CAR T-cell therapy that modifies a patient's own T cells to target and destroy cancer cells.

Interpreter Notes

Interpreters should be aware that Breyanzi may be referred to by its generic name, lisocabtagene maraleucel, in some contexts. It is crucial to maintain a formal register when discussing this medication, as it is used in specialized oncology settings. Avoid colloquial terms or informal language when interpreting for healthcare professionals.

Example Sentences

EN: The oncologist recommended Breyanzi as a treatment option for the patient's relapsed large B-cell lymphoma.

ES: El oncólogo recomendó Breyanzi como una opción de tratamiento para el linfoma de células B grandes en recaída del paciente.

Common Interpreter Mistakes

Confusing Breyanzi with other CAR T-cell therapies; mispronouncing the name leading to misunderstanding; using informal language when discussing a clinical treatment.